S-4472-119
Held at the desk.
Sponsored by Lisa Murkowski (R-AK)
What it does
This bill would reauthorize the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031, extending federal grant funding for ALS (Lou Gehrig's disease) research and expanded access programs. It would also strengthen oversight of those grants by requiring applicants to report safety data from ongoing clinical trials and requiring the FDA to review enrollment and efficacy data before renewing grants. Additionally, it would require the FDA to update its action plan for ALS and other rare neurodegenerative diseases every five years and require HHS to submit a congressional report assessing program effectiveness within four years of enactment.
Who benefits
ALS patients and their families, who would continue to have access to investigational drugs through federally funded expanded access programs. Patients with other rare neurodegenerative diseases (e.g., Parkinson's, Huntington's) who may benefit from the broadened FDA action plan. Academic and nonprofit research institutions that receive ALS research grants. Pharmaceutical and biotech companies developing ALS therapies, who gain a continued federal partner in the drug development pipeline. Caregivers of ALS patients who may benefit from accelerated therapy development.
Who is hurt
Drug manufacturers whose investigational drugs are under grant review may face increased disclosure burdens, as they would be required to share interim clinical trial data and safety information with the FDA. Grant applicants whose drugs show poor enrollment or weak interim data could face non-renewal. Taxpayers bear the cost of continued federal spending on the program. Patients with other rare diseases not covered by the program may see no benefit despite the broader framing.
Supporters argue
Supporters argue that ALS is a uniformly fatal disease with no cure, affecting roughly 30,000 Americans at any given time, and that the original 2021 Act created a critical pipeline for experimental therapies that would otherwise be inaccessible to patients. They contend that the new oversight provisions — requiring safety data reporting and enrollment reviews before grant renewals — strengthen accountability and ensure federal dollars are directed toward the most promising therapies, improving both patient safety and research efficiency.
Opponents argue
Opponents argue that reauthorizing the program without a rigorous independent evaluation of its outcomes to date risks perpetuating spending on a framework whose effectiveness has not been fully demonstrated. They contend that requiring manufacturers to share interim clinical trial data with the FDA as a condition of grant renewal could compromise the integrity of blinded trials, introduce regulatory pressure into the scientific process, and potentially deter smaller biotech firms from participating in the program.
Constitutional context
Congress funds this program under the Taxing and Spending Clause (Art. I, §8, cl. 1), which grants broad authority to spend for the general welfare. FDA regulatory oversight of investigational drugs is grounded in the Commerce Clause (Art. I, §8, cl. 3). No active constitutional tension is present; this is a straightforward reauthorization of an existing program within well-established congressional authority.
Checks and balances
Congress gains continued authority over ALS research funding through appropriations; the FDA and HHS gain expanded oversight and reporting responsibilities, while Congress retains oversight through mandated GAO and HHS reports submitted to the relevant committees.
Historical precedent
The original Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) was enacted in 2021 and established this grant and expanded access framework; this bill is a direct reauthorization of that program.